Last reviewed 2026-05-21 · How we verify

Rellidep

Mount Sinai Hospital, Canada · Phase 2 active Small molecule ✓ Verified May 2026

Rellidep is a Small molecule drug developed by Mount Sinai Hospital, Canada. It is currently in Phase 2 development.

Rellidep is a treatment being studied for its safety and antidepressant effects in patients with major depressive disorder. According to ClinicalTrials.gov, Rellidep is being investigated in an open-label pilot study for its potential to treat depression.

Likelihood of approval

15.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	Rellidep
Sponsor	Mount Sinai Hospital, Canada
Modality	Small molecule
Therapeutic area	Other
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Safety and Antidepressant Effects of Rellidep in Major Depressive Disorder (PHASE2, PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Rellidep CI brief — competitive landscape report
Rellidep updates RSS · CI watch RSS
Mount Sinai Hospital, Canada portfolio CI

Frequently asked questions about Rellidep

What is Rellidep?

Rellidep is a Small molecule drug developed by Mount Sinai Hospital, Canada.

Who makes Rellidep?

Rellidep is developed by Mount Sinai Hospital, Canada (see full Mount Sinai Hospital, Canada pipeline at /company/mount-sinai-hospital-canada).

What development phase is Rellidep in?

Rellidep is in Phase 2.

Manufacturer: Mount Sinai Hospital, Canada — full pipeline
Therapeutic area: All drugs in Other

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing